ArticleInternal medicine (Tokyo, Japan)2018
Emergence of Carbapenem Non-susceptible Campylobacter coli after Long-term Treatment against Recurrent Bacteremia in a Patient with X-linked Agammaglobulinemia.
Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- The clinical characteristics and outcomes of Campylobacter spp. bloodstream infection: A systematic review and meta-analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- First Detection of Critical Carbapenemase Genes (NDM, OXA-48, VIM) in AvianAntibiotics (Basel, Switzerland) · 2025Article
- Comparative Genomic Analysis of Livestock-DerivedJournal of microbiology and biotechnology · 2025Article
- Carbapenem resistant Campylobacter jejuni bacteremia in a Bruton's X-linked agammaglobulinemia patient.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Development of Meropenem Resistance in a Multidrug-Resistant Campylobacter coli Strain Causing Recurrent Bacteremia in a Hematological Malignancy Patient.Antimicrobial agents and chemotherapy · 2023Article
- Recurrent Campylobacter jejuni Infections withMicrobiology spectrum · 2023Article
- Pericarditis due to Campylobacter coli infection: a case report.BMC infectious diseases · 2023Article
- Relapsing cellulitis associated with Campylobacter coli bacteremia in a Good's syndrome patient: a case report.BMC infectious diseases · 2022Article
- Assessment of biofilm formation by Campylobacter spp. isolates mimicking poultry slaughterhouse conditions.Poultry science · 2022Article
- Antibiotic Resistance in the Alternative Lifestyles ofFrontiers in cellular and infection microbiology · 2021Article
- Article
- Recurrent Campylobacter Enteritis in Patients with Hypogammaglobulinemia: Review of the Literature.Journal of clinical medicine · 2020Review
- Technical specifications on harmonised monitoring of antimicrobial resistance in zoonotic and indicator bacteria from food-producing animals and food.EFSA journal. European Food Safety Authority · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We herein report a case of recurrent Campylobacter coli bacteremia in a 37-year-old Japanese man with X-linked agammaglobulinemia (XLA). The patient experienced seven episodes of C. coli bacteremia over one year, with an erythematous rash intermittently emerged on the lower limbs. Although hospitalization for intravenous treatment was repeatedly recommended, he obstinately declined it. Following long-term oral antibiotic treatment with tebipenem and faropenem for the persistent infection, C. coli showed elevated minimum inhibitory concentrations to meropenem, a key drug for severe campylobacteriosis. Physicians should note that the overuse of antibiotics can lead to the emergence of carbapenem-non-susceptible Campylobacter strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.